#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
haura nar raananaa	٥٦							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BELANOFF JOSEPH K					2. Issuer Name <b>and</b> Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [ CORT ]											ck all app Direc	olicable) ctor		erson(s) to I	Owner		
			t) ( RAPEUTICS LTH DRIVE	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 07/10/2006										X	X Officer (give title below) Other (specify below)  Chief Executive Officer				
(Street) MENLO PARK CA 94025				-   4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)											Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
(City)		(Stat		Zip)		<u> </u>																
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transac Date (Month/Da			ction	tion 2A. Deem Execution y/Year) if any		Deemed ution Date,		3. Transaction Code (Instr. 8)		4. Securitie	es Ac	Acquired (A) of (D) (Instr. 3, 4		r	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
											Code	v	Amount	(A) or (D)		Price	e	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock																	300	),000		I	Custodian for a minor daughter <sup>(1)</sup>
Common Stock																	300	),000		I	Custodian for minor son <sup>(1)</sup>	
Common Stock 07/10/				2006					S <sup>(2)</sup>		1,000		D \$		i4	2,213,195		D				
Common Stock 07/12				2006					<b>S</b> <sup>(2)</sup>		100		D	\$4.35		2,213,095		D				
Common Stock 07/12/2				2006	2006				<b>S</b> <sup>(2)</sup>		1,400 D \$		\$4.	.34	2,211,795		D					
			Та										osed of, onvertib					wned				
Derivative Security (Instr. 3)  Conversion or Exercise Price of Derivative Security  Date (Month/Day/Year)  (Month/Day/Year)  Execution Date, if any (Month/Day/Year)			4. Transa Code ( 8)	(Instr.	nstr. Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date E Expirati (Month/II	on Da		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		of s ng e (Instr. 3 mount r lumber	8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

### **Explanation of Responses:**

- 1. The Reporting Person is the custodian for minor children and disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
- $2. \ The sale on this Form 4 was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 15, 2004.$

# Remarks:

s/s Fred Kurland, CFO of **Corcept Therapeutics** Incorporated attorney-in-fact

07/12/2006

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.